Syntopix is a specialised research and development business, focusing on the discovery of topical antimicrobials for healthcare and pharmaceutical applications through the repositioning of known chemical entities that have a history of use in humans.
We seek to identify compounds and develop products that treat dermatological conditions, principally acne and topical staphylococcal infections, including those due to MRSA.
Our world class antimicrobial expertise is now also being successfully applied to other areas as we develop collaborative relationships with major healthcare companies.
14/04/2009 06:47
EXCLUSIVE EVALUATION AGREEMENT
Syntopix signs an exclusive evaluation agreement with a major consumer healthcare company…
06/08/2008 13:13
Syntopix proposal to raise £1.5million passed by shareholders...
03/07/2008 07:00
Syntopix enters into joint development agreement with Procter & Gamble...
25/02/2008 07:00
Syntopix announces positive results from its Phase II cosmetic study...